Skip to main content

Lonafarnib for cancer and progeria.

Publication ,  Journal Article
Wong, NS; Morse, MA
Published in: Expert Opin Investig Drugs
July 2012

INTRODUCTION: Lonafarnib is a non-peptidomimetic inhibitor of farnesyl transferase, an enzyme responsible for the post-translational lipid modification of a wide variety of cellular proteins that are involved in the pathogenic pathways of various diseases including cancer and progeria. Although extensive clinical research indicates limited activity of lonafarnib in solid tumors, there is recent interest in combinations of farnesyl transferase inhibitors with imatinib or bortezomib in hematological malignancies and to investigate the role of lonafarnib in progeria. AREAS COVERED: This review examines the in vitro and in vivo pharmacology of lonafarnib and the available clinical data for lonafarnib monotherapy and combination therapy in the treatment of solid and hematological malignancies as well as progeria, using studies identified from the PubMed database supplemented by computerized search of relevant abstracts from major cancer and hematology conferences. EXPERT OPINION: There is no evidence to support the use of lonafarnib in solid tumors. There is ongoing interest to explore lonafarnib for progeria and to investigate other farnesyl transferase inhibitors for chronic and acute leukemias.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Opin Investig Drugs

DOI

EISSN

1744-7658

Publication Date

July 2012

Volume

21

Issue

7

Start / End Page

1043 / 1055

Location

England

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Treatment Outcome
  • Pyridines
  • Protein Prenylation
  • Progeria
  • Piperidines
  • Pharmacology & Pharmacy
  • Neoplasms
  • Humans
  • Farnesyltranstransferase
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wong, N. S., & Morse, M. A. (2012). Lonafarnib for cancer and progeria. Expert Opin Investig Drugs, 21(7), 1043–1055. https://doi.org/10.1517/13543784.2012.688950
Wong, Nan Soon, and Michael A. Morse. “Lonafarnib for cancer and progeria.Expert Opin Investig Drugs 21, no. 7 (July 2012): 1043–55. https://doi.org/10.1517/13543784.2012.688950.
Wong NS, Morse MA. Lonafarnib for cancer and progeria. Expert Opin Investig Drugs. 2012 Jul;21(7):1043–55.
Wong, Nan Soon, and Michael A. Morse. “Lonafarnib for cancer and progeria.Expert Opin Investig Drugs, vol. 21, no. 7, July 2012, pp. 1043–55. Pubmed, doi:10.1517/13543784.2012.688950.
Wong NS, Morse MA. Lonafarnib for cancer and progeria. Expert Opin Investig Drugs. 2012 Jul;21(7):1043–1055.

Published In

Expert Opin Investig Drugs

DOI

EISSN

1744-7658

Publication Date

July 2012

Volume

21

Issue

7

Start / End Page

1043 / 1055

Location

England

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Treatment Outcome
  • Pyridines
  • Protein Prenylation
  • Progeria
  • Piperidines
  • Pharmacology & Pharmacy
  • Neoplasms
  • Humans
  • Farnesyltranstransferase